Advancing and improving the treatment of deep venous disease

Mr. Bruce Shook is a highly-experienced, medical device executive with more than 30 years of industry experience, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. Mr. Shook formed Vesper Medical in 2016 as a spinout of Intact Vascular. Mr. Shook served as President & CEO of both Intact Vascular and Vesper Medical until Intact Vascular was purchased by Royal Philips in 2020. Prior to Vesper Medical and Intact Vascular, Mr. Shook was co-founder, Director, President and CEO of Neuronetics [NASDAQ: STIM], which markets a non-invasive brain stimulation technology for the treatment of depression.

Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders and President of Abiomed [NASDAQ: ABMD] where he successfully obtained PMA approval for the first, FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.

Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University. Mr. Shook currently serves on the Board of Directors at Devoro Medical, the Penn State Research Foundation and Life Sciences PA. He previously served as a Director at Surgiquest, Respicardia and CoTherix.

Mark J. Garcia, MD, F.S.I.R., F.A.C.R., is a leading interventional radiologist who has held positions of Medical Director of the Center for Comprehensive Venous Health and Chief of Interventional Radiology at Christiana Care Health Services in Newark, Delaware. Dr. Garcia began his own practice, EndoVascular Consultants, and practices at St. Francis Hospital in addition to his own interventional outpatient lab. Previously, he served as the Chief Medical Officer for Merit Medical, a company developing disposable devices for interventional procedures.

Dr. Garcia received his medical degree from Thomas Jefferson Medical College and has a MS in genetics from the University of Illinois, Chicago and a BS in biology from Arizona State University.

Mr. Joseph C. Griffin, III has more than 35 years of experience in the design, development, regulatory compliance and manufacturing of numerous leading-edge, cardiovascular devices. Mr. Griffin joined Vesper Medical in 2016 when it was formed as a spinout of Intact Vascular. He served as Vice President of Regulatory Affairs/Quality Assurance and Compliance Officer for both companies until Intact Vascular was purchased by Royal Phillips in 2020. Mr. Griffin is the official company representative for all domestic and international quality, regulatory and compliance activities.

Previously, he served as Vice President of Regulatory Affairs and Compliance Officer at Flexible Stenting Solutions, a subsidiary of Cordis Corporation. In this role, he executed various regulatory, quality, clinical and compliance duties that led to the Cordis acquisition in 2013. Before, Mr. Griffin founded Professional Catheter Corporation, where he served as President until the EP MedSystems acquisition in 1993.

Upon acquisition, he was appointed Vice President of Regulatory Affairs and played a key role in EP MedSystems IPO in 1995 (NASDAQ: EPMD). He also served as Director of Research and Development at Oscor Medical Corporation and Director of Research, Development and Technical Services at Nova Medical Specialties, leading to its acquisition by B. Braun of America in 1987.

Mr. Griffin attended several academic institutions and earned numerous certificates in Medical Plastics Technology, Silicone & Polyurethane for Medical Applications, Advanced Medical Plastics, ISO 13485 and Auditing. He is a published co-author in the area of medical device thrombogenicity research and an inventor/co-inventor, who holds 15 medical device-related U.S. patents.

With a background in quality, regulatory and manufacturing, Mr. Mike Longo started with Vesper Medical in 2016 with its inception as a spinout of Intact Vascular. He held responsibilities for both companies to manage the pipeline of innovative product development and oversee R&D and operational activities until Intact Vascular was sold to Royal Philips in 2020. He has extensive medical device engineering experience that includes a strong knowledge of Quality Systems Regulations, ISO 9001 and 13485 as well as management experience for Class I, II and III development programs for cardiovascular and diabetes care products.

Previously, Mr. Longo served as a Staff Design Quality Engineer at Animas Corporation, a Johnson & Johnson Company. Before then, he was an Engineering Manager at Bioconnect Systems with responsibilities for developing an arteriovenous fistula implant and reusable delivery instruments. Mr. Longo also worked at Kensey Nash (now DSM) in senior-level product development and manufacturing engineering roles.

Mr. Longo earned a B.S. degree in Electro-Mechanical Engineering from Pennsylvania State University.

With more than 15 years of experience managing all phases of clinical research for medical devices, Mr. Marc Penna started with Vesper Medical in 2016 as the company was started as a spinout of Intact Vascular where Mr. Penna held the same position until its sale to Royal Philips in 2020. He is responsible for creating short and long-term clinical strategies with a focus on enhancing trial enrollment.

He has held both executive and clinical data/clinical trial program management roles within the cardiovascular, endovascular and oncology therapeutic areas. Previously, he served as the Senior Director of Clinical and Medical Affairs at AngioDynamics, where he was responsible for all global clinical activity. Earlier in his career, Mr. Penna worked on the transcatheter aortic valve replacement (TAVR) pivotal trials at Edwards Life Sciences as well as on the drug eluting stent program at Boston Scientific.

Mr. Penna holds a B.S. in Management Information Systems from Central Connecticut State University.

Having joined Vesper Medical at its inception in 2016 as a spinout of Intact Vascular where she joined as the Controller in 2014 and remained until its sale to Royal Philips in 2020, Ms. Monica Klos is responsible for coordinating company planning, forecasting and budgeting, financial reporting and all accounting operations.

She has more than 30 years of accounting and financial experience, primarily in the life science industry. Formerly, she was the Controller for NuPathe, where she was responsible for SEC financial reporting, compliance, accounting and budget oversight, and equity compensation. Ms. Klos had previously served as the Controller for Neose Technologies. She began her career with KPMG before holding positions of increasing responsibility at various life science companies.

Ms. Klos received a B.S. degree in Accounting from Villanova University and is a Certified Public Accountant in Pennsylvania.

Mrs. Suzanne Wallace has more than 10 years of experience with medical devices in various roles across marketing, education and medical affairs. She has joined Vesper Medical to lead efforts to prepare for commercialization of the Vesper Duo Stent System™.

Previously, she served as Director of Medical Education and Scientific Communications at Shockwave Medical where she had dual medical affairs and marketing responsibilities for their global portfolio of products. Earlier in her career, Mrs. Wallace was the Director of Field Marketing and Education in Medtronic’s Mechanical Circulatory Support Business (Heartware, Inc.) where she was responsible for all aspects of commercial marketing and customer training programs.

Mrs. Wallace is a board certified Nurse Practitioner with a post-master’s degree in family practice and a Master of Science in nursing with a specialization in emergency and critical care. She spent the majority of her clinical career at the Penn State Hershey Medical Center caring for patients with cardiovascular disease. She received her B.S.N from Messiah College and both her M.S.N and Post-Master’s Certificate from Widener University.

Mrs. Andrea Dunkle is currently the Director of Human Resources and Administration for Vesper Medical as well as responsible for investor and media relations. She previously served as the Director of Human Resources and Facilities at Intact Vascular, Inc. and was with the company from 2012 through September 2020.

Vesper Medical was added to her responsibilities in 2016 at which time she performed a dual role of overseeing Intact Vascular and Vesper Medical’s policies and benefits, as well as the general administration and facilities for both. Intact Vascular was acquired in September 2020 and Mrs. Dunkle shifted soley to Vesper Medical.

Prior to joining Intact Vascular, Mrs. Dunkle served as the Finishing Superintendent/Estimator at C.F. Holloway, III & Co.

Mrs. Dunkle received a B.B.A. from Loyola University, Baltimore, MD and is a Society of Human Resources Certified Professional and a Professional of Human Resources with Human Resources Certification Institute^®.